Sepia is developing oligonucleotide based breakthrough molecular therapies in Cancer, infectious diseases and immunomodulation.

 

About

Sepia is an international specialist healthcare group with its head office in Hamburg, Germany. SMH is developing oligonucleotide-based breakthrough molecular therapies in Cancers and infectious diseases, holding two innovative platform technologies: G-Quadruplex DNA technology and siRNA-Prodrug technology, and a portfolio of twelve products at different clinical stages. The first product is to be introduced in the market in 2024.

Development Strategy

Sepia strategically targets high unmet clinical needs in Infectious disease and Cancer, where Fast Track and Breakthrough Designation is likely. This allows product development with smaller trials and commercialisation using small sales forces servicing specialist hospital physicians, reducing development, regulatory and commercialisation costs and speeding up access to the market.

Sepia’s general value creation policy is to develop its own products and partner/ license its larger indication products at a late stage for final development or commercialisation. 

Sepia has teamed up with academic institutions to expedite the development of the siRNA and DNA-technology platforms to treat cancer and infectious diseases. This industry-university collaboration channels rapid transfer of results from the forefront of academic scientific research to focused development of smart medication relying on the vast industrial know-how of the pharmaceutical industry.

Clinical product portfolio

Sepia has twelve products, eight of which are drug candidates under the Virion Dome platform targeting infectious diseases, three are drug candidates under the Cancer Dome platform, and one product is a rapid diagnostic test for Sepsis pathogen identification under the Diagnostics Dome platform.

Sepia's first product, already filed with the FDA, will be launched under the Virion Dome platform in 2024, preventing the recurrence of Herpes (skin).

One-Stop-Shop

Sepia offers a ‘one-stop-innovation hub’ developing breakthrough molecular therapies in Cancers and infectious diseases. Sepia does not intend to produce treatments for the mass market itself. Instead, Sepia’s strategy is to acquire pharmaceutical development partners with market access and expertise in clinical development.

Virion Dome

The Virion Dome platform focuses on developing siRNA and DNA-based therapies for treating viral diseases such as Herpes (HSV-1+2), SARS (Covid-19) and others.

Cancer Dome

The Cancer Dome platform focuses on developing siRNA–based therapies to prevent metastatic development after primary surgery and treat local metastatic events.

Diagnostics Dome

Our diagnostics device is a simple, low-blood volume, bedside compatible workflow that allows high sensitivity and specificity in bacterial and virus-induced sepsis using molecular, macrophage-enhanced techniques.


Report abuse